Last reviewed 2026-04-23 · How we verify

Vancomycin 1.1%

Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.

Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of serious or severe bacterial infections caused by susceptible strains of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and other susceptible Gram-positive bacteria..

At a glance

Mechanism of action

This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin has a high affinity for the bacterial cell wall and is able to inhibit cell wall synthesis even at low concentrations.

Approved indications

• Treatment of serious or severe bacterial infections caused by susceptible strains of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and other susceptible Gram-positive bacteria.

Common side effects

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Anemia
• Thrombocytopenia
• Renal impairment
• Hypokalemia
• Hypomagnesemia

Key clinical trials

• Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vancomycin 1.1% CI brief — competitive landscape report
• Vancomycin 1.1% updates RSS · CI watch RSS
• Kurobe LLC portfolio CI